Floatz logo

Anti-Cd19/22-Car Vector-Transduced T Cells

Prolymphocytic Leukemia

Chinese PLA General HospitalCell therapyPhase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

22 Active assets in the Prolymphocytic Leukemia cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Center for International Blood and Marrow Transplant Research
Phase 2BBB
Fludarabine
Center for International Blood and Marrow Transplant Research
Phase 3BB
Monomethyl Fumarate
Center for International Blood and Marrow Transplant Research
Phase 3BB
FILGRASTIM
Center for International Blood and Marrow Transplant Research
Phase 2BB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

Anti-Cd19/22-Car Vector-Transduced T Cells is also rated in:

Hematopoietic/Lymphoid CancerDormant
CCC
Indicative ·
48 / 100
View asset →
B-Cell Chronic Lymphocytic Leukemia in Relapse (Diagnosis)Dormant
CCC
Indicative ·
48 / 100
View asset →
B-cell Adult Acute Lymphoblastic LeukemiaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →